Effect of application and intensity of bevacizumab-based maintenance after induction chemotherapy with bevacizumab for metastatic colorectal cancer: A meta-analysis

Clinical Colorectal Cancer

Volumn 15, Issue 2, 2016, Pages e29-e39

  Stein, Alexander ^a   Schwenke, Carsten ^b   Folprecht, Gunnar ^c   Arnold, Dirk ^a,d  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b Strategies and Solutions in Statistics   (Germany)

^c UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^d CUF Hospital   (Portugal)

Author keywords

Bevacizumab; Fluoropyrimidines; Maintenance; Metastatic Colorectal Cancer

Indexed keywords

BEVACIZUMAB; FLUOROPYRIMIDINE;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; HUMAN; INDUCTION CHEMOTHERAPY; META ANALYSIS; METASTATIC COLORECTAL CANCER; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; COLORECTAL NEOPLASMS; DISEASE FREE SURVIVAL; FEMALE; MAINTENANCE CHEMOTHERAPY; MALE; METASTASIS; MORTALITY; PATHOLOGY; PROCEDURES; TREATMENT OUTCOME;

BEVACIZUMAB; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INDUCTION CHEMOTHERAPY; MAINTENANCE CHEMOTHERAPY; MALE; NEOPLASM METASTASIS; TREATMENT OUTCOME;

EID: 84953431924     PISSN: 15330028     EISSN: 19380674     Source Type: Journal    
DOI: 10.1016/j.clcc.2015.12.005     Document Type: Article

References (22)

1. J. Ferlay, I.I. Soerjomataram, R. Dikshit, and et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012 Int J Cancer 136 2015 E359 E386
2. R. Siegel, C. Desantis, and A. Jemal Colorectal cancer statistics, 2014 CA Cancer J Clin 64 2014 104 117
3. J.Y. Douillard, K.S. Oliner, S. Siena, and et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer N Engl J Med 369 2013 1023 1034
4. A. Venook, D. Niedzwiecki, H.J. Lenz, F. Innocenti, and M. Mahoney CALGB/SWOG 80405: phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC) J Clin Oncol 32 suppl 2014 abstract LBA3
5. V. Heinemann, L.F. von Weikersthal, T. Decker, and et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial Lancet Oncol 15 2014 1065 1075
6. F. Loupakis, C. Cremolini, G. Masi, and et al. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer N Engl J Med 371 2014 1609 1618
7. R. Labianca, A. Sobrero, L. Isa, and et al. Intermittent versus continuous chemotherapy in advanced colorectal cancer: a randomised "GISCAD" trial Ann Oncol 22 2011 1236 1242
8. C. Tournigand, A. Cervantes, A. Figer, and et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer - a GERCOR study J Clin Oncol 24 2006 394 400
9. H.S. Hochster, A. Grothey, L. Hart, and et al. Improved time to treatment failure with an intermittent oxaliplatin strategy: results of CONcePT Ann Oncol 25 2014 1172 1178
10. A. Johnsson, H. Hagman, J.E. Frodin, and et al. A randomized phase III trial on maintenance treatment with bevacizumab alone or in combination with erlotinib after chemotherapy and bevacizumab in metastatic colorectal cancer: the Nordic ACT trial Ann Oncol 24 2013 2335 2341
11. B. Chibaudel, F. Maindrault-Goebel, G. Lledo, and et al. Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study J Clin Oncol 27 2009 5727 5733
12. H. Wasan, A.M. Meade, R. Adams, and et al. Intermittent chemotherapy plus either intermittent or continuous cetuximab for first-line treatment of patients with KRAS wild-type advanced colorectal cancer (COIN-B): a randomised phase 2 trial Lancet Oncol 15 2014 631 639
13. L.H. Simkens, H. van Tinteren, A. May, and et al. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group Lancet 385 2015 1843 1852
14. D. Koeberle, D.C. Betticher, R. von Moos, and et al. Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41/06) Ann Oncol 26 2015 709 714
15. S. Hegewisch-Becker, U. Graeven, B. Killing, R. Depenbusch, and C.C. Steffens Maintenance strategies after initial first-line oxaliplatin/fluoropyrimidine/bevacizumab for patients with metastatic colorectal cancer: AIO 0207, a randomized, open-label, phase 3 trial Lancet Oncol 16 2015 1355 1369
16. C. Tournigand, B. Chibaudel, B. Samson, and et al. Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer (GERCOR DREAM; OPTIMOX3): a randomised, open-label, phase 3 trial Lancet Oncol 16 2015 1493 1505
17. S. Yalcin, R. Uslu, F. Dane, and et al. Bevacizumab + capecitabine as maintenance therapy after initial bevacizumab + XELOX treatment in previously untreated patients with metastatic colorectal cancer: phase III "Stop and Go" study results - a Turkish Oncology Group Trial Oncology 85 2013 328 335
18. E. Diaz-Rubio, A. Gomez-Espana, B. Massuti, and et al. First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study Oncologist 17 2012 15 25
19. C. Tournigand, B. Samson, and W. Scheithauer Bevacizumab (Bev) with or without erlotinib as maintenance therapy, following induction first-line chemotherapy plus Bev, in patients with metastatic colorectal cancer (mCRC): efficacy and safety results of the international GERCOR DREAM phase III trial J Clin Oncol 30 suppl 2012 abstract LBA3500
20. The Nordic Cochrane Centre, The Cochrane Collaboration, RevMan version 5.1, User Guide - Review Manager (RevMan) [Computer program]. 2011; version 5.1.
21. H.C. Bucher, G.H. Guyatt, L.E. Griffith, and S.D. Walter The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials J Clin Epidemiol 50 1997 683 691
22. G. Aprile, F. Giuliani, S.E. Lutrino, and et al. Maintenance therapy in colorectal cancer: moving the artillery down while keeping an eye on the enemy [e-pub ahead of print] Clin Colorectal Cancer 2015 10.1016/j.clcc.2015.08.002